$ELUT
ELUTIA INC.

2021 Q3 Form 10-Q Financial Statement

#000155837021015500 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q4 2020 Q3
Revenue $11.49M $12.47M $11.77M
YoY Change -2.45% 3.49% 5.69%
Cost Of Revenue $7.796M $6.450M $6.233M
YoY Change 25.08% -9.92% 11.3%
Gross Profit $3.689M $6.020M $5.541M
YoY Change -33.42% 23.11% 0.02%
Gross Profit Margin 32.12% 48.28% 47.06%
Selling, General & Admin $8.376M $8.710M $6.968M
YoY Change 20.21% 17.07% 1.28%
% of Gross Profit 227.05% 144.68% 125.75%
Research & Development $2.289M $1.270M $1.264M
YoY Change 81.09% 92.42% 147.84%
% of Gross Profit 62.05% 21.1% 22.81%
Depreciation & Amortization $932.0K $940.0K $970.0K
YoY Change -3.92% -3.09% 0.0%
% of Gross Profit 25.26% 15.61% 17.51%
Operating Expenses $10.67M $9.980M $8.232M
YoY Change 29.56% 23.21% 11.39%
Operating Profit -$6.976M -$3.960M -$2.691M
YoY Change 159.23% 23.36% 45.46%
Interest Expense $1.328M -$1.390M $1.465M
YoY Change -9.35% -4.14% -217.2%
% of Operating Profit
Other Income/Expense, Net $0.00 -$2.567M
YoY Change -100.0%
Pretax Income -$8.304M -$5.350M -$6.723M
YoY Change 23.52% 93.14% 116.87%
Income Tax $12.00K $10.00K $8.000K
% Of Pretax Income
Net Earnings -$8.300M -$5.360M -$6.731M
YoY Change 23.31% 92.81% 117.13%
Net Earnings / Revenue -72.27% -42.98% -57.17%
Basic Earnings Per Share -$0.81 -$15.79
Diluted Earnings Per Share -$0.81 -$523.9K -$15.79
COMMON SHARES
Basic Shares Outstanding 10.24M 648.4K
Diluted Shares Outstanding 10.24M 648.4K

Balance Sheet

Concept 2021 Q3 2020 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.54M $39.15M $1.540M
YoY Change 1363.83%
Cash & Equivalents $22.54M $39.15M $1.544M
Short-Term Investments
Other Short-Term Assets $1.360M $3.270M $3.790M
YoY Change -64.12%
Inventory $9.832M $10.12M $9.790M
Prepaid Expenses
Receivables $5.519M $7.166M $7.100M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $39.25M $59.71M $22.21M
YoY Change 76.74%
LONG-TERM ASSETS
Property, Plant & Equipment $1.257M $1.162M $1.140M
YoY Change 10.26%
Goodwill
YoY Change
Intangibles $19.32M $21.87M
YoY Change
Long-Term Investments
YoY Change
Other Assets $76.00K $76.00K $80.00K
YoY Change -5.0%
Total Long-Term Assets $20.65M $23.10M $23.93M
YoY Change -13.71%
TOTAL ASSETS
Total Short-Term Assets $39.25M $59.71M $22.21M
Total Long-Term Assets $20.65M $23.10M $23.93M
Total Assets $59.90M $82.81M $46.14M
YoY Change 29.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.689M $2.054M $3.250M
YoY Change -48.03%
Accrued Expenses $5.232M $6.323M $7.870M
YoY Change -33.52%
Deferred Revenue
YoY Change
Short-Term Debt $8.059M $6.310M $0.00
YoY Change
Long-Term Debt Due $8.059M $6.310M $8.760M
YoY Change -8.0%
Total Short-Term Liabilities $22.51M $26.78M $25.59M
YoY Change -12.04%
LONG-TERM LIABILITIES
Long-Term Debt $12.05M $17.81M $21.68M
YoY Change -44.44%
Other Long-Term Liabilities $17.49M $756.0K $17.19M
YoY Change 1.73%
Total Long-Term Liabilities $12.05M $18.57M $38.87M
YoY Change -69.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.51M $26.78M $25.59M
Total Long-Term Liabilities $12.05M $18.57M $38.87M
Total Liabilities $52.04M $61.98M $64.45M
YoY Change -19.25%
SHAREHOLDERS EQUITY
Retained Earnings -$96.00M -$80.26M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.859M $20.83M -$74.90M
YoY Change
Total Liabilities & Shareholders Equity $59.90M $82.81M $46.14M
YoY Change 29.83%

Cashflow Statement

Concept 2021 Q3 2020 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income -$8.300M -$5.360M -$6.731M
YoY Change 23.31% 92.81% 117.13%
Depreciation, Depletion And Amortization $932.0K $940.0K $970.0K
YoY Change -3.92% -3.09% 0.0%
Cash From Operating Activities -$3.098M -$5.370M -$1.230M
YoY Change 151.87% 108.14% -48.75%
INVESTING ACTIVITIES
Capital Expenditures -$97.00K -$110.0K -$440.0K
YoY Change -77.95% -31.25% 175.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$97.00K -$110.0K -$440.0K
YoY Change -77.95% -31.25% 175.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $43.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.547M 43.37M 2.270M
YoY Change -212.2% 814.98% -10.63%
NET CHANGE
Cash From Operating Activities -3.098M -5.370M -1.230M
Cash From Investing Activities -97.00K -110.0K -440.0K
Cash From Financing Activities -2.547M 43.37M 2.270M
Net Change In Cash -5.742M 37.89M 600.0K
YoY Change -1057.0% 1794.5% -3100.0%
FREE CASH FLOW
Cash From Operating Activities -$3.098M -$5.370M -$1.230M
Capital Expenditures -$97.00K -$110.0K -$440.0K
Free Cash Flow -$3.001M -$5.260M -$790.0K
YoY Change 279.87% 117.36% -64.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10235350
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
648436
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10229974
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
648331
dei Entity Central Index Key
EntityCentralIndexKey
0001708527
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10235350
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
648436
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10229974
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
648331
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-30.82
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-30.82
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39577
dei Entity Registrant Name
EntityRegistrantName
Aziyo Biologics, Inc.
dei Entity Address Address Line1
EntityAddressAddressLine1
Delaware
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4790334
dei Entity Address City Or Town
EntityAddressCityOrTown
Silver Spring
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20904
dei City Area Code
CityAreaCode
240
dei Local Phone Number
LocalPhoneNumber
247-1170
dei Security12b Title
Security12bTitle
Class A Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
AZYO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10727000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7350000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22543000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39150000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
83000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
382000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5519000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7166000
CY2021Q3 us-gaap Inventory Net
InventoryNet
9832000
CY2020Q4 us-gaap Inventory Net
InventoryNet
10117000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1277000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2892000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
39254000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
59707000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1257000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1162000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19316000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
21865000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
76000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
76000
CY2021Q3 us-gaap Assets
Assets
59903000
CY2020Q4 us-gaap Assets
Assets
82810000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1689000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2054000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5232000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6323000
CY2021Q3 azyo Payables To Tissue Suppliers Current
PayablesToTissueSuppliersCurrent
2714000
CY2020Q4 azyo Payables To Tissue Suppliers Current
PayablesToTissueSuppliersCurrent
2295000
CY2021Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
8059000
CY2020Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
6310000
CY2021Q3 azyo Revenue Interest Obligation Current
RevenueInterestObligationCurrent
2750000
CY2020Q4 azyo Revenue Interest Obligation Current
RevenueInterestObligationCurrent
2750000
CY2021Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1956000
CY2020Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
6514000
CY2021Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
110000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
533000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
22510000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26779000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12046000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17811000
CY2021Q3 azyo Revenue Interest Obligation Noncurrent
RevenueInterestObligationNoncurrent
16552000
CY2020Q4 azyo Revenue Interest Obligation Noncurrent
RevenueInterestObligationNoncurrent
16633000
CY2021Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
936000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
756000
CY2021Q3 us-gaap Liabilities
Liabilities
52044000
CY2020Q4 us-gaap Liabilities
Liabilities
61979000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103876000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101080000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96027000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80259000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
7859000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
20831000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59903000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82810000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11485000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3593000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2667000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11774000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
36529000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
30216000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7796000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6233000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
20897000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15676000
CY2021Q3 us-gaap Gross Profit
GrossProfit
3689000
CY2020Q3 us-gaap Gross Profit
GrossProfit
5541000
us-gaap Gross Profit
GrossProfit
15632000
us-gaap Gross Profit
GrossProfit
14540000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4783000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4301000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14285000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12845000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2289000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1264000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5890000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3981000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
10665000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
8232000
us-gaap Operating Expenses
OperatingExpenses
30902000
us-gaap Operating Expenses
OperatingExpenses
24176000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6976000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2691000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15270000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9636000
CY2021Q3 us-gaap Interest Expense
InterestExpense
1328000
CY2020Q3 us-gaap Interest Expense
InterestExpense
1465000
us-gaap Interest Expense
InterestExpense
4034000
us-gaap Interest Expense
InterestExpense
4248000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2567000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3579000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2567000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8304000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6723000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15725000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16451000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-8316000
azyo Increase Decrease In Obligations To Tissue Suppliers
IncreaseDecreaseInObligationsToTissueSuppliers
-55000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6731000
us-gaap Net Income Loss
NetIncomeLoss
-15768000
us-gaap Net Income Loss
NetIncomeLoss
-16469000
CY2020Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
3510000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
3510000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8316000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10241000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15768000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19979000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-30.82
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10235350
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
648436
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10229974
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
648331
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
14967000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
208000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1000000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-8316000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
7859000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-64723000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2020Q3 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
3510000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
58000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6731000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-74904000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
20831000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
208000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2562000
us-gaap Net Income Loss
NetIncomeLoss
-15768000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
7859000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-55111000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
3510000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
184000
us-gaap Net Income Loss
NetIncomeLoss
-16469000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-74904000
us-gaap Profit Loss
ProfitLoss
-15768000
us-gaap Profit Loss
ProfitLoss
-16469000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2797000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2921000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3029000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2340000
azyo Gain Loss On Revaluation Of Revenue Interest Obligation And Other
GainLossOnRevaluationOfRevenueInterestObligationAndOther
-227000
azyo Increase Decrease In Contract With Customer Liability And Other Liabilities
IncreaseDecreaseInContractWithCustomerLiabilityAndOtherLiabilities
-209000
azyo Increase Decrease In Contract With Customer Liability And Other Liabilities
IncreaseDecreaseInContractWithCustomerLiabilityAndOtherLiabilities
-290000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
91000
azyo Interest Expense Recorded As Additional Revenue Interest Obligation
InterestExpenseRecordedAsAdditionalRevenueInterestObligation
1987000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
91000
azyo Interest Expense Recorded As Additional Revenue Interest Obligation
InterestExpenseRecordedAsAdditionalRevenueInterestObligation
2011000
azyo Interest Expense Recorded As Convertible Preferred Stock
InterestExpenseRecordedAsConvertiblePreferredStock
39000
us-gaap Share Based Compensation
ShareBasedCompensation
2562000
us-gaap Share Based Compensation
ShareBasedCompensation
184000
us-gaap Other Noncash Expense
OtherNoncashExpense
814000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1647000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-134000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-285000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2598000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1615000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2248000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1456000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4641000
azyo Increase Decrease In Obligations To Tissue Suppliers
IncreaseDecreaseInObligationsToTissueSuppliers
419000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9059000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8258000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
344000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
525000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-344000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-525000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2000000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-4558000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
1639000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
3441000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
2995000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1111000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
300000
azyo Payments On Revenue Interest Obligation
PaymentsOnRevenueInterestObligation
2068000
azyo Payments On Revenue Interest Obligation
PaymentsOnRevenueInterestObligation
1940000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
208000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7503000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7837000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16906000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-946000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39532000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2590000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22626000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1644000
us-gaap Interest Paid Net
InterestPaidNet
3788000
us-gaap Interest Paid Net
InterestPaidNet
3769000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
37000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
32000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2000000
azyo Forgiveness Of Sba Paycheck Protection Program Loan
ForgivenessOfSbaPaycheckProtectionProgramLoan
3029000
CY2020Q4 us-gaap Share Price
SharePrice
17.00
CY2020Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
43000000.0
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
13.9549
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2941176
CY2020Q4 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
3500000
CY2020Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3500000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-8300000
us-gaap Net Income Loss
NetIncomeLoss
-15800000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96000000.0
CY2021Q3 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
556000
CY2021Q3 us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
per month
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassifications</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain reclassifications have been made to prior year amounts to conform with current year financial statement presentation.  The reclassifications relate to certain executive compensation costs and technical operations expenses at the Company’s Richmond, California plant. As follows are the total amounts reclassified for the three and nine months ended September 30, 2020 along with the line items in the condensed consolidated statement of operations that were impacted (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.87%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:49.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Increase (Decrease) From Previously Reported Amounts</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 127</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 374</p></td></tr><tr><td style="vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (528)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,544)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 401</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,170</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">These reclassifications did not impact the Company’s consolidated earnings or assets for the three and nine months ended September 30, 2020.</p>
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1644000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">amounts of revenues and expenses during the reporting period. Estimates and assumptions relating to inventory, receivables, long-lived assets, the valuation of stock-based awards, the valuation of the preferred stock warrant liability and deferred income taxes are made at the end of each financial reporting period by management. Management continually re-evaluates its estimates, judgments and assumptions, and management's evaluation could change. Actual results could differ from those estimates.</p>
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1544000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
83000
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22626000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22543000
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. At September 30, 2021, the Company maintained $23.3 million in bank deposit accounts that are in excess of the $0.25 million insurance provided by the Federal Deposit Insurance Corporation in one federally insured financial institution. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:10pt 0pt 10pt 0pt;">The Company sells certain of its products under large contract manufacturing or distribution arrangements. The following table presents percentage of total revenues derived from the Company’s largest customers as well as their respective percentage of total accounts receivable:<span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:88.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"/></div></td><td style="vertical-align:bottom;width:15.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"/></div></td><td style="vertical-align:bottom;width:15.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"/></div></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:15.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"/></div></td><td style="vertical-align:bottom;width:15.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"/></div></td></tr><tr style="height:11.25pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:top;width:30.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:30.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr style="height:11.6pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:15.31%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:15.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:15.28%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;width:15.26%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:11.25pt;"><td style="background-color:#cceeff;vertical-align:top;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:12pt;text-indent:-12pt;margin:0pt;">Percent of revenues derived from:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.28%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="background-color:#cceeff;vertical-align:bottom;width:15.26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/></tr><tr style="height:12pt;"><td style="vertical-align:top;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="white-space:pre-wrap;"> Medtronic Sofamor Danek USA</span></p></td><td style="vertical-align:bottom;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">3%</p></td><td style="vertical-align:bottom;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">18%</p></td><td style="vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">14%</p></td><td style="vertical-align:bottom;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">16%</p></td></tr><tr style="height:11.25pt;"><td style="background-color:#cceeff;vertical-align:top;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="white-space:pre-wrap;"> Surgalign Holdings</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">9%</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">10%</p></td><td style="background-color:#cceeff;vertical-align:top;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">10%</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:15.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">9%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="letter-spacing:0.2pt;margin-bottom:10pt;margin-top:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"/></div></td><td style="vertical-align:bottom;width:22.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"/></div></td><td style="vertical-align:bottom;width:22.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"/></div></td></tr><tr style="height:11.6pt;"><td style="vertical-align:bottom;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2021</b></p></td><td style="vertical-align:bottom;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr style="height:11.25pt;"><td style="background-color:#cceeff;vertical-align:top;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:12pt;text-indent:-12pt;margin:0pt;">Percent of accounts receivable derived from:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/><td style="background-color:#cceeff;vertical-align:bottom;width:22.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"/></tr><tr style="height:12pt;"><td style="vertical-align:top;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="white-space:pre-wrap;"> Medtronic Sofamor Danek USA</span></p></td><td style="vertical-align:bottom;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">0%</p></td><td style="vertical-align:bottom;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">34%</p></td></tr><tr style="height:11.25pt;"><td style="background-color:#cceeff;vertical-align:top;width:54.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="white-space:pre-wrap;"> Surgalign Holdings</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">12%</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;">13%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2021Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
23300000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
147883
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
17.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
91182
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
3180
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
13.86
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
235885
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
16.08
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2562000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
186000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0096
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0189
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1944000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1507000
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1098000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
708000
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6790000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7902000
CY2021Q3 us-gaap Inventory Net
InventoryNet
9832000
CY2020Q4 us-gaap Inventory Net
InventoryNet
10117000
CY2017Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10000000
CY2017Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
8000000
CY2021Q3 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
556000
CY2021Q3 us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
per month
CY2019Q3 azyo Casualty Proceeds Percentage In Excess Of Agreed Amount To Apply To Prepayment Of Debt
CasualtyProceedsPercentageInExcessOfAgreedAmountToApplyToPrepaymentOfDebt
1
CY2019Q3 azyo Casualty Proceeds Amount Over Which To Apply To Prepayment
CasualtyProceedsAmountOverWhichToApplyToPrepayment
250000
CY2019Q3 azyo No Ordinary Sales Of Assets Or Borrowing Base Proceeds To Apply To Debt Prepayment
NoOrdinarySalesOfAssetsOrBorrowingBaseProceedsToApplyToDebtPrepayment
1
us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
41
CY2021Q3 azyo Number Of Claims Recall No Lawsuit
NumberOfClaimsRecallNoLawsuit
35
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
20105000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
24121000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
8059000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
6310000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12046000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17811000
CY2020Q3 azyo Interest Expense Recorded As Additional Revenue Interest Obligation
InterestExpenseRecordedAsAdditionalRevenueInterestObligation
700000
CY2021Q3 azyo Interest Expense Recorded As Additional Revenue Interest Obligation
InterestExpenseRecordedAsAdditionalRevenueInterestObligation
700000
azyo Interest Expense Recorded As Additional Revenue Interest Obligation
InterestExpenseRecordedAsAdditionalRevenueInterestObligation
2000000.0
azyo Interest Expense Recorded As Additional Revenue Interest Obligation
InterestExpenseRecordedAsAdditionalRevenueInterestObligation
2000000.0
azyo Sale Of Stocks Payable Upon Consummation
SaleOfStocksPayableUponConsummation
750000
azyo Number Of Production Facilities Under Operating Lease
NumberOfProductionFacilitiesUnderOperatingLease
2
azyo Number Of Administrative And Research Facility Under Operating Lease
NumberOfAdministrativeAndResearchFacilityUnderOperatingLease
1
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
CY2021Q3 azyo Loss Contingency Number Of Insurance Carriers
LossContingencyNumberOfInsuranceCarriers
2
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8316000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10241000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15768000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19979000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10235350
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
648436
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10229974
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
648331
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-30.82
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1626119
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3937342
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11485000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11774000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
36529000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
30216000

Files In Submission

Name View Source Status
0001558370-21-015500-index-headers.html Edgar Link pending
0001558370-21-015500-index.html Edgar Link pending
0001558370-21-015500.txt Edgar Link pending
0001558370-21-015500-xbrl.zip Edgar Link pending
azyo-20210930.xsd Edgar Link pending
azyo-20210930x10q.htm Edgar Link pending
azyo-20210930x10q_htm.xml Edgar Link completed
azyo-20210930xex31d1.htm Edgar Link pending
azyo-20210930xex31d2.htm Edgar Link pending
azyo-20210930xex32d1.htm Edgar Link pending
azyo-20210930xex32d2.htm Edgar Link pending
azyo-20210930_cal.xml Edgar Link unprocessable
azyo-20210930_def.xml Edgar Link unprocessable
azyo-20210930_lab.xml Edgar Link unprocessable
azyo-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending